Abstract
Thirteen patients with Raynaud's phenomenon secondary to systemic sclerosis received three 8-hour infusions of a synthetic prostacyclin analogue (Iloprost) on consecutive days and were followed-up over a period of 10 weeks during the winter of 1985/86. Six weeks after infusion, digital peripheral vascular resistance had fallen (P less than 0.05) and dicrotic notch proportion of pulse amplitude increased (P less than 0.05). Digital blood flow and pulse amplitude (measured by photoplethymography) were also increased but did not reach statistical significance. The trend of improvement in these blood flow parameters was still evident after 10 weeks. The number of cutaneous lesions (digital ulcers, etc) fell from 26 lesions before infusion to only 7 lesions by the end of the study, confirming the subjective improvement reported by the patients.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Belch J. J., McKay A., McArdle B., Leiberman P., Pollock J. G., Lowe G. D., Forbes C. D., Prentice C. R. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet. 1983 Feb 12;1(8320):315–317. doi: 10.1016/s0140-6736(83)91625-2. [DOI] [PubMed] [Google Scholar]
- Belch J. J., Newman P., Drury J. K., McKenzie F., Capell H., Leiberman P., Forbes C. D., Prentice C. R. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet. 1983 Feb 12;1(8320):313–315. doi: 10.1016/s0140-6736(83)91624-0. [DOI] [PubMed] [Google Scholar]
- Cooke E. D., Bowcock S. A., Smith A. T. Photoplethysmography of the distal pulp in the assessment of the vasospastic hand. Angiology. 1985 Jan;36(1):33–40. doi: 10.1177/000331978503600106. [DOI] [PubMed] [Google Scholar]
- Cooke E. D., Bowcock S. A., Watkins C. J., Rustin M. H., Kirby J. D. CL115,347, an analogue of prostaglandin E2. Peripheral circulatory effects of single ascending doses administered transdermally in normal subjects and in patients with Raynaud's phenomenon. Angiology. 1985 Dec;36(12):867–871. doi: 10.1177/000331978503601205. [DOI] [PubMed] [Google Scholar]
- Cowley A. J., Heptinstall S., Hampton J. R. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man. Thromb Haemost. 1985 Feb 18;53(1):90–94. [PubMed] [Google Scholar]
- Dowd P. M., Martin M. F., Cooke E. D., Bowcock S. A., Jones R., Dieppe P. A., Kirby J. D. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol. 1982 Jan;106(1):81–89. doi: 10.1111/j.1365-2133.1982.tb00905.x. [DOI] [PubMed] [Google Scholar]
- Dunger D. B., Dillon M. J., Daman-Willems C., Cooke E. D., Bowcock S. A. Treatment of childhood Raynaud's disease by transdermal prostaglandin E2 analogue. Lancet. 1985 Jul 6;2(8445):50–50. doi: 10.1016/s0140-6736(85)90108-4. [DOI] [PubMed] [Google Scholar]
- Gryglewski R. J., Moncada S., Palmer R. M. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol. 1986 Apr;87(4):685–694. doi: 10.1111/j.1476-5381.1986.tb14586.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kahaleh M. B., Sherer G. K., LeRoy E. C. Endothelial injury in scleroderma. J Exp Med. 1979 Jun 1;149(6):1326–1335. doi: 10.1084/jem.149.6.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kyle V., Parr G., Salisbury R., Thomas P. P., Hazleman B. Prostaglandin E1 vasospastic disease and thermography. Ann Rheum Dis. 1985 Feb;44(2):73–78. doi: 10.1136/ard.44.2.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meyer O., Haïm T., Dryll A., Lansaman J., Ryckewaert A. Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol. 1983 Jan-Mar;1(1):29–34. [PubMed] [Google Scholar]